ArticleIranian Red Crescent medical journal2013
Demographic and histological predictors of survival in patients with gastric and esophageal carcinoma.
Article in Iranian Red Crescent medical journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Survival of gastric cancer patients in Iran: a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2023Review
- Incidence, Survival and Prognostic Factors of Oesophagogastric Cancer.Journal of gastrointestinal cancer · 2022Article
- Leveraging hybrid biomarkers in clinical endpoint prediction.BMC medical informatics and decision making · 2020Article
- Comparison of Cancer Prevalence in Physicians with That of the General Population, and Important Considerations.Korean journal of family medicine · 2016Article
- Survival rate of gastric cancer in Iran; a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2016Review
- Determination of Effective Factors on Survival of GI Cancers: Results of Five Years Follow up in Iranian Population.Global journal of health science · 2015Article
- Clinical-pathological characteristics and prognosis of a cohort of oesophageal cancer patients: a competing risks survival analysis.Journal of epidemiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the possible influence of demographic and histological risk factors on the survival of patients with esophageal and gastric cancer.
objectivesBased on the available registry and follow-up information, this study compares 1-5 year survival rate of gastric and esophageal cancer. PATIENTS AND
methodsThrough a concurrent (prospective) cohort study, all 366 patients with definite diagnosis of esophageal and gastric cancer who had been hospitalized at the Towhid Hospital, Sanandaj city, Kurdistan province, western Iran during a five-year period from 2006 onwards were recruited. The survival time of patients stratified by this grouping method were analyzed by Kaplan-Meier analysis and Cox regression.
resultsAmongst the 366 patients, 23 had esophageal adenocarcinoma, 94 esophageal squamous-cell carcinoma and 239 had gastric adenocarcinoma. Age at diagnosis (P = < 0.001), tumor grade (P = 0.008) and practice treatment (P = < 0.001) had significant associations with the variation of survival rates in patients with esophageal but not with gastric cancer. The five-year survival rates (by year) for esophageal cancer were 49%, 27%, 24%, 22% and 19%, respectively and for gastric cancer were 41%, 17%, 13%, 10% and 5.4%, respectively.
conclusionsMajor differences between these cancers were seen in the survival rates of patients and their incidence classified by sex. Age at diagnosis and histological types were prognostic factors for survival of patients with esophageal cancer but this wasn't the case for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.